Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

Dr Alexander (Sandy) Douglas in a medical research laboratory

Dr Sandy Douglas was awarded a 5 year Wellcome Stage 2 Clinical Research Career Development Fellowship, receiving £1.3m of funding to investigate development of new vaccines against rabies and Epstein Barr virus. On the back of his strong fellowship application, he also was one of four recipients of a Wellcome-Beit prize, worth another £25k of funding. This prize is awarded annually to Wellcome’s strongest applicants across their range of intermediate-level clinical & non-clinical fellowship schemes.

Dr Sandy Douglas commented upon receiving the news: “I’m really grateful to Wellcome for the opportunity to start work on vaccines against Epstein Barr virus. As well as glandular fever the virus causes many cancers and seems to be a prerequisite for development of multiple sclerosis, but it’s a tricky target and has been quite neglected by vaccine developers. The Jenner & the wider NDM are the perfect setting to enable progress in this important area.”

Similar stories

New computational technique reveals changes to lung function post COVID-19 infection

A new study led by Oxford researchers found that prior COVID-19 infection was associated with more uneven inflation of the lungs during normal breathing, smaller lung volumes, and greater respiratory dead space.

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

Celebrating Childhood Cancer Awareness Month

September was Childhood Cancer Awareness Month, and researchers in Department of Paediatrics took action to help raise awareness for this cause.

New study shows higher rate of fractures in people with intellectual disability

In the most comprehensive study of its kind, researchers at the University of Oxford and Oxford Health NHS Foundation Trust found a substantially higher rate of fractures in people with intellectual disability compared with people of the same age and gender without an intellectual disability.

New evidence for how our brains handle surprise

A new study from the Bruno Group is challenging our perceptions of how the different regions of the cerebral cortex function. A group of ‘quiet’ cells in the somatosensory cortex that rarely respond to touch have been found to react mainly to surprising circumstances. The results suggest their function is not necessarily driven by touch, but may indicate an important and previously unidentified role across all the major cortices.